Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 333Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 240Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 170Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 119Prednisone 118Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Doxorubicin 98Leucovorin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 78Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × ASTX029 × Clear all
NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
192 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡